GlassScriptPhysician profile
Zoheb Osman
NPI 1881074599
$2,680.18
in general payments reported to CMS, 2019-2025
23 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2022: $326 · 2023: $365 · 2024: $737 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.97 | 2022-2025 | |
| Lilly USA, LLC | $437.50 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $290.96 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $266.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $250.09 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $161.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $94.80 | 2019 | |
| Exact Sciences Corporation | $74.02 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $55.23 | 2024-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $47.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.59 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $43.96 | 2019 | |
| Pfizer INC. | $38.31 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.09 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.20 | 2025 | Nuvaring, Nexplanon |
| Novartis Pharmaceuticals Corporation | $26.97 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.79 | 2025 | Voquezna |
| Mayne Pharma Commercial LLC | $20.35 | 2022 | |
| Exeltis, USA INC. | $16.59 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $15.16 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $14.20 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoheb Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.